July 6, 2005 – PsychoGenics Inc. Tarrytown, New York has signed a license agreement enabling it to provide behavioral phenotyping and compound evaluation services using the transgenic R6/2 mouse model for Huntington Disease. Huntington Disease is a devastating and ultimately fatal neurological condition for which no treatment currently exists. The Huntington animal model provides a valuable discovery tool to aid in the development of much needed drugs.Under the terms of the license agreement, PsychoGenics is now able to provide third-party testing in the R6/2 model. The terms of the agreement are undisclosed, however, there are no reach-through obligations on PsychoGenics’ clients.